The companies to combine their technologies to develop novel theranostic radiopharmaceuticals.

Merck to supply folate derivatives for the preparation...

Full releases >>

Houston (TX, USA) and Garching (Germany), July 26, 2018 – RadioMedix Inc. and ITM Isotopen Technologien München (ITM), a group of specialized...

Full releases >>

Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617

Full releases >>

Bruce Power to secure global supply of no-carrier-added Lutetium-177 through 2064.

ITM to achieve new scalability of n.c.a Lutetium-177...

Full releases >>

Recruitment in the U.S. for the COMPETE trial to begin shortly.

Solucin® studied as a first-line therapy.

Exclusively-produced...

Full releases >>

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the appointment of Philip E. Harris, BSc MB...

Full releases >>

ITM receives marketing authorization for a ready-to-use radiopharmaceutical in 3 European countries. TOCscan® will be the companion diagnostic in...

Full releases >>

Acknowledgement of ITM’s success in bringing a new promising therapy in Precision Oncology to market and to the patients

Full releases >>

Mit der Unterstützung der Initiative „Diversity als Chance – die Charta der Vielfalt der Unternehmen in Deutschland“ setzt ITM Isotopen Technologien...

Full releases >>

Endocyte, Inc., and ITM Isotopen Technologien München AG (ITM) today announced a supply agreement under which ITM will supply to Endocyte the medical...

Full releases >>